Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 7Phase 3 2Phase 4 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 39Other hematologic neoplasm 17Gastrointestinal 17Lymphoid 15Thoracic 13Breast 10Gynecologic 7Myeloid 6Dermatologic 5Genitourinary 4Sarcoma 3Tumor-Agnostic 2Head & Neck 2Plasma cell 1Endocrine 1CNS 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 141Lenalidomide 60Bortezomib 56Calcium Dobesilate 47Melphalan 44carfilzomib 40pomalidomide 39Cyclophosphamide 38daratumumab 27belantamab mafodotin 22ixazomib 19Peripheral Blood Stem Cell Transplantation 18fludarabine phosphate 16fludarabine 16dexamethasone acetate 14Bendamustine Hydrochloride 14Whole-Body Irradiation 13Filgrastim 13dexamethasone 21-phosphate 12Tacrolimus 12venetoclax 11auricularum 11Prednisone 11selinexor 10liposomal doxorubicin 10iberdomide 10Mycophenolic Acid 10Cyclosporine 9pembrolizumab 8isatuximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Injections × Plasma cell × Clear all
NCT06049290 2025-12-04

A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Recruiting
342 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡